ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2026)
ARS Pharmaceuticals recorded quarterly EBITDA Margin of 268.24% in Q1 2026, down 82.9% quarter-over-quarter from 146.66% in Q4 2025, and up 15931.0% year-over-year from N/an in Q1 2025.
ARS Pharmaceuticals' EBITDA Margin history runs 5 years deep, the most recent figure standing at 268.24% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 15931.0% year-over-year to 268.24%; the TTM figure through Mar 2026 stood at 200.17% (down 18426.0% YoY), while the FY2025 annual figure was 203.37%, down 21253.0% from the prior year.
- EBITDA Margin came in at 268.24% for Q1 2026 at ARS Pharmaceuticals, down from 146.66% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 57.54% in Q4 2024 to a low of 176180.0% in Q2 2023.
- A 5-year average of 20252.13% and a median of 901.55% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin slumped 17479638 bps in 2023 and jumped 17367260 bps in 2024, its largest moves.
- ARS Pharmaceuticals' EBITDA Margin stood at 3483.07% in 2022, then slumped by 4958 bps to 176180.0% in 2023, then jumped by 100 bps to 57.54% in 2024, then tumbled by 355 bps to 146.66% in 2025, then tumbled by 83 bps to 268.24% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 268.24%, 146.66%, and 157.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -268.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.24% |
| Dec 31, 2025 | -146.66% |
| Sep 30, 2025 | -157.26% |
| Jun 30, 2025 | -286.32% |
| Mar 31, 2025 | -427.54% |
| Dec 31, 2024 | 57.54% |
| Sep 30, 2024 | -901.55% |
| Jun 30, 2024 | -2,507.40% |
| Jun 30, 2023 | -176,180.00% |
| Mar 31, 2023 | -76,500.00% |
| Sep 30, 2022 | -3,483.07% |
| Jun 30, 2022 | -1,383.62% |
| Mar 31, 2022 | -1,093.51% |